GlassScriptPhysician profile
Michelle G Briley
NPI 1336789387
$723.61
in general payments reported to CMS, 2019-2025
17 companies · $670 in 2025
The $670 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $53.89 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.07 | 2025 | |
| Lilly USA, LLC | $120.63 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $73.75 | 2025 | Farxiga, Breztri |
| Amgen INC. | $56.00 | 2025 | Evenity |
| Pfizer INC. | $54.05 | 2025 | |
| Exact Sciences Corporation | $30.29 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $29.10 | 2025 | Arexvy, Shingrix, Boostrix |
| Novo Nordisk INC | $28.93 | 2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $27.13 | 2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $25.08 | 2025 | Trintellix |
| Sumitomo Pharma America, INC. | $20.93 | 2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $20.21 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $17.51 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.49 | 2025 | |
| Seqirus USA INC | $15.97 | 2025 | Fluad, Flucelvax |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.91 | 2025 | Jardiance |
| Dexcom, INC. | $13.56 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Briley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.